1. Lawrence D, Kisely S, Pais J. The epidemiology of excess mortality in peoplewith mental illness. Can J Psychiatry 2010;55:752-760.
3. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, et al. The distribution of bodymass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-220.
4. Coodin S. Body mass index in persons with schizophrenia. Can J Psychiatry 2001;46:549-555.
5. Goldman LS. Medical illness in patients with schizophrenia. J Clin Psychiatry 1999;60:10-15.
6. Sasaki J, Kumagae G, Sata T, Kuramitsu M, Arakawa K. Decreased concentration of high density lipoprotein cholesterol in schizophrenic patients treated with phenothiazines. Atherosclerosis 1984;51:163-169.
7. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-296.
8. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-289.
10. Vieweg V, Levenson J, Pandurangi A, Silverman J. Medical disorders in the schizophrenic patient. Int J Psychiatry Med 1995;25:137-172.
11. Folsom DP, McCahill M, Bartels SJ, Lindamer LA, Ganiats TG, Jeste DV. Medical comorbidity and receipt of medical care by older homeless people with schizophrenia or depression. Psychiatr Serv 2002;53:1456-1460.
12. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz A, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
14. Suka M, Sugimori H, Yoshida K. Application of the updated Framingham risk score to Japanese men. Hypertens Res 2001;24:685-689.
15. Marrugat J, Solanas P, D’Agostino R, Sullivan L, Ordovas J, Cordón F, et al. Coronaryrisk estimation in Spain using a calibrated Framingham function. Rev Esp Cardiol 2003;56:253-261.
16. Liu J, Hong Y, D’Agostino RB, Wu Z, Wang W, Sun J, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004;291:2591-2599.
17. Eichler K, Puhan MA, Steurer J, Bachmann LM. Prediction of first coronary events with the Framingham score: a systematic review. Am Heart J 2007;153:722-731.
18. Lee J, Heng D, Ma S, Chew SK, Hughes K, Tai ES. The metabolic syndrome and mortality: the Singapore Cardiovascular Cohort Study. Clin Endocrinol (Oxf) 2008;69:225-230.
19. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005;80:45-53.
21. Cohn T, Prud’homme D, Streiner D, Kameh H, Remington G. Characterizing coronaryheart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004;49:753-760.
22. Bobes J, Arango C, Garcia-Garcia M, Rejas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of theimpact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res 2010;119:101-109.
24. Jin H, Folsom D, Sasaki A, Mudaliar S, Henry R, Torres M, et al. Increased Framingham 10-year risk of coronary heart diseasein middleaged and older patients with psychotic symptoms. Schizophr Res 2011;125:295-299.
25. Ratliff JC, Palmese LB, Reutenauer EL, Srihari VH, Tek C. Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular riskand vascular ages than obese individuals without severe mental illness. Psychosomatics 2013;54:67-73.
26. Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. A comparison of schizophrenia outpatients treated with antipsychotics with and withoutmetabolic syndrome: findings from the CLAMORS study. Schizophr Res 2008;104:1-12.
27. Barak Y, Swartz M, Plopsky I. Assessing cardiovascular risks of olanzapine treatment: a 6-month study versus haloperidol in schizophrenia patients. Int Clin Psychopharmacol 2005;20:315-317.
29. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generationantipsychotic drugs. J Clin Psychiatry 2006;67:575-583.
31. McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003;183:534-539.
32. Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 2012;25:83-88.
33. Arangoa C, Bobes J, Kirkpatrick B, Garcia-Garcia M, Rejas J. Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: Findings from the CLAMORS study. Eur Neuropsychopharmacol 2011;21:867-875.
34. Andreasen NC. Methods for assessing positive and negative symptoms. Mod Probl Pharmacopsychiatry 1990;24:73-88.
35. Addington D, Addington J, Maticka-Tyndale E. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992;6:201-208.
36. Erkoç Ş, Arkonaç O, Ataklı C, Özmen E. Reliability and validity of the Turkish version of Scale for the Assessment of Positive Symptoms. Düşünen Adam 1991;4:20-24.
37. Erkoç Ş, Arkonaç O, Ataklı C, Özmen E. Reliability and validity of the Turkish version of Scale for the Assessment of Negative Symptoms. Düşünen Adam 1991;4:16-19.
38. Aydemir Ö, Danacı AE, Pırıldar ŞA, Deveci A, İçelli İ. Reliability and validity of the Turkish version of Scale for the Assessment of Calgary Depression Scale for Schizophrenia. Arch Neuropsychiatry 2000;37:210-213.
39. Tay YH, Nurjono M, Lee J. Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia. Schizophr Res 2013;147:187-192.
40. Zhao S, Xia H, Mu J, Wang L, Zhu L, Wang A, et al. 10-year CVD risk in Han Chinese mainland patients with schizophrenia. Psychiatry Res 2018;264:322-326.
42. Raphael TP, Parsons JP. Blood sugar studies in dementia praecox and manic-depressive insanity. Arch Neurol Psychiatry 1921;5:687-709.
43. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry 2003;160:284-289.
44. Hansen T, Ingason A, Djurovic S, Melle I, Fenger M, Gustafsson O, et al. At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol Psychiatry 2011;70:59-63.
46. Bai YM, Chen TT, Liou YJ, Hong CJ, Tsai SJ. Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. Schizophr Res 2011;125:179-186.
47. Burghardt K, Grove T, Ellingrod V. Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia. J Psychopharmacol 2014;28:349-356.
52. De Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviours. Schizophr Res 2005;76:135-157.
53. Chapman S, Ragg M, McGeechan K. Citation bias in reportedsmoking prevalence in people with schizophrenia. Aus N Z J Psychiatry 2009;43:277-282.
54. de Leon J. Smoking and vulnerability for schizophrenia. Schizophr Bull 2006;22:405-409.
55. Poirier MF, Canceil O, Baylé F, Millet B, Bourdel MC, Moatti C, et al. Prevalence of smoking in psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:529-537.
56. de Leon J, Susce MT, Diaz FJ, Rendon DM, Velásquez DM. Variables associated with alcohol, drug, and daily smoking cessation inpatients with severe mental illnesses. J Clin Psychiatry 2005;66:1447-1455.
57. Barr AM, Procyshyn RM, Hui P, Johnson JL, Honer WG. Selfreported motivation to smoke in schizophrenia is related to antipsychoticdrug treatment. Schizophr Res 2008;100:252-260.
58. Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, et al. Missing metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 2007;21:357-373.
59. Von Hausswolff-JuhlinY, Bjartveit M, Lindström E, Jones P. Schizophreniaand physical health problems. Acta Psychiatr Scand Suppl 2009;438:15-21.
62. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin B. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004;65:1-12.
63. Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 2009;113:1-11.
64. Baxter A, Harris M, Khatib Y, Brugha T, Bien H, Bhui K. Reducing excess mortality due to chronic disease in people with severe mental illness: meta-review of health interventions. Br J Psychiatry 2016;208:322-329.
66. Huang KL, Fang CJ, Hsu CC, Wu SI, Juang JJ, Stewart R. Myocardial infarction risk and antipsychotics use revisited: a meta-analysis of 10 observational studies. J Psychopharmacol 2017;31:1544-1555.
67. Wildi H, Najim H. Clinical outcomes of depot and well being clinic. Results of physical health care checks. Psychiatr Danub 2011;25(Suppl 2):S174-S177.
68. Sanchez-Martinez V, Romero-Rubio D, Abad-Perez MJ, DescalzoCabades MA, Alonso-Gutierrez S, Salazar-Fraile J, et al. Metabolic syndrome and cardiovascular risk in people treated with long-acting injectable antipsychotics. Endocr Metab Immune Disord Drug Targets 2018;18:379-387.
69. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther 2008;30:2378-2386.
70. Rosa F, Schreiner A, Thomas P, Sherif T. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Clin Drug Investig 2012;32:267-279.